NO983724L - 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase - Google Patents

17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase

Info

Publication number: NO983724L
Authority: NO; Norway
Prior art keywords: compounds; reductase; androgen; mediated; aza
Prior art date: 1996-02-14

Application number

NO983724A

Other languages

English (en)

Norwegian (no)

Other versions

NO983724D0 (no

Inventor

James R Pribish

Cynthia A Gates

Philip M Weintraub

Original Assignee

Hoechst Marion Roussel Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-14

Filing date

1998-08-13

Publication date

1998-10-13

1998-08-13 Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc

1998-08-13 Publication of NO983724D0 publication Critical patent/NO983724D0/no

1998-10-13 Publication of NO983724L publication Critical patent/NO983724L/no

Links

MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 2
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 title 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229960003604 testosterone Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
208000035475 disorder Diseases 0.000 abstract 4
230000001404 mediated effect Effects 0.000 abstract 4
239000003098 androgen Substances 0.000 abstract 3
239000000262 estrogen Substances 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
IXELLVJONWOKSN-NQDKFLQJSA-N (1S,3aS,3bS,9aR,9bS,11aS)-1-(cyclopropylamino)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one Chemical compound N([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)N=C4CC3)C)CC[C@@]21C)C1CC1 IXELLVJONWOKSN-NQDKFLQJSA-N 0.000 abstract 1
208000002874 Acne Vulgaris Diseases 0.000 abstract 1
229940123407 Androgen receptor antagonist Drugs 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract 1
208000014311 Cushing syndrome Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
206010000496 acne Diseases 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
239000003936 androgen receptor antagonist Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO983724A 1996-02-14 1998-08-13 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase NO983724L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60127896A	1996-02-14	1996-02-14
PCT/US1997/000469 WO1997030069A1 (en)	1996-02-14	1997-01-09	17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase

Publications (2)

Publication Number	Publication Date
NO983724D0 NO983724D0 (no)	1998-08-13
NO983724L true NO983724L (no)	1998-10-13

Family

ID=24406899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO983724A NO983724L (no)	1996-02-14	1998-08-13	17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase

Country Status (17)

Country	Link
EP (1)	EP0880540B1 (es)
JP (1)	JP2000505444A (es)
KR (1)	KR19990082543A (es)
CN (1)	CN1211256A (es)
AT (1)	ATE219100T1 (es)
AU (1)	AU710208B2 (es)
BR (1)	BR9708301A (es)
CA (1)	CA2244823A1 (es)
DE (1)	DE69713285T2 (es)
DK (1)	DK0880540T3 (es)
ES (1)	ES2178750T3 (es)
HU (1)	HUP9900955A3 (es)
IL (1)	IL125575A0 (es)
NO (1)	NO983724L (es)
NZ (1)	NZ327041A (es)
PT (1)	PT880540E (es)
WO (1)	WO1997030069A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6187925B1 (en) *	1997-12-23	2001-02-13	Merck & Co., Inc.	Intermediates and process for the synthesis of azasteroids
US6465445B1 (en) *	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en)	1998-06-11	2006-02-28	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CA2431171A1 (en) *	2000-12-08	2002-06-13	Takeda Chemical Industries, Ltd.	Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
CA2524409C (en)	2003-05-07	2011-12-20	Merck & Co., Inc.	Androgen receptor modulators and methods of use thereof
PE20090931A1 (es) *	2007-10-29	2009-08-03	Takeda Pharmaceutical	Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
US20100105700A1 (en) *	2008-10-28	2010-04-29	Lead Therapeutics, Inc.	Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
US20110178065A1 (en) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Novel cyp17 inhibitors
GB201102913D0 (en)	2011-02-18	2011-04-06	Univ Birmingham	Novel therapeutic
CN109438549B (zh) *	2018-12-13	2022-01-04	湖北葛店人福药业有限责任公司	一种制备N-叔丁基-3-氧代-4-氮杂-5α-雄甾-17β-甲酰胺的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264427A (en) *	1992-01-29	1993-11-23	Research Corporation Technologies, Inc.	20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
UA35589C2 (uk) *	1992-05-21	2001-04-16	Андорешерш Інк.	ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
US5486511A (en) *	1993-05-25	1996-01-23	Merrell Dow Pharmaceuticals Inc.	4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase

1997
- 1997-01-09 JP JP9529338A patent/JP2000505444A/ja active Pending
- 1997-01-09 ES ES97901995T patent/ES2178750T3/es not_active Expired - Lifetime
- 1997-01-09 CA CA002244823A patent/CA2244823A1/en not_active Abandoned
- 1997-01-09 EP EP97901995A patent/EP0880540B1/en not_active Expired - Lifetime
- 1997-01-09 CN CN97192283A patent/CN1211256A/zh active Pending
- 1997-01-09 AU AU15767/97A patent/AU710208B2/en not_active Ceased
- 1997-01-09 WO PCT/US1997/000469 patent/WO1997030069A1/en not_active Ceased
- 1997-01-09 NZ NZ327041A patent/NZ327041A/xx unknown
- 1997-01-09 AT AT97901995T patent/ATE219100T1/de not_active IP Right Cessation
- 1997-01-09 DE DE69713285T patent/DE69713285T2/de not_active Expired - Fee Related
- 1997-01-09 DK DK97901995T patent/DK0880540T3/da active
- 1997-01-09 PT PT97901995T patent/PT880540E/pt unknown
- 1997-01-09 HU HU9900955A patent/HUP9900955A3/hu unknown
- 1997-01-09 BR BR9708301A patent/BR9708301A/pt not_active IP Right Cessation
- 1997-01-09 KR KR1019980706280A patent/KR19990082543A/ko not_active Ceased
- 1997-01-09 IL IL12557597A patent/IL125575A0/xx unknown
1998
- 1998-08-13 NO NO983724A patent/NO983724L/no unknown

Also Published As

Publication number	Publication date
CN1211256A (zh)	1999-03-17
PT880540E (pt)	2002-10-31
NZ327041A (en)	1999-11-29
EP0880540A1 (en)	1998-12-02
HUP9900955A3 (en)	2000-06-28
ES2178750T3 (es)	2003-01-01
IL125575A0 (en)	1999-03-12
DE69713285T2 (de)	2003-01-02
HUP9900955A2 (hu)	1999-07-28
NO983724D0 (no)	1998-08-13
AU1576797A (en)	1997-09-02
DK0880540T3 (da)	2002-10-07
CA2244823A1 (en)	1997-08-21
JP2000505444A (ja)	2000-05-09
AU710208B2 (en)	1999-09-16
WO1997030069A1 (en)	1997-08-21
KR19990082543A (ko)	1999-11-25
ATE219100T1 (de)	2002-06-15
DE69713285D1 (en)	2002-07-18
BR9708301A (pt)	1999-08-03
EP0880540B1 (en)	2002-06-12

Publication	Publication Date	Title
CA2050291A1 (en)	1990-09-11	Combination therapy for the treatment of estrogen sensitive diseases
NO983724L (no)	1998-10-13	17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase
DK1556058T3 (da)	2008-03-03	Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
IL260127B (en)	2022-04-01	mek inhibitors and methods of using them
ATE229506T1 (de)	2002-12-15	1-(2-oxo-acetyl)-piperidin-2-carbonsäure derivate als sensibilisatoren für multi-drug-resistente krebszellen
NO20043531L (no)	2004-10-25	Indazolforbindelser som er nyttige som proteinkinaseinhibitorer
DK279790A (da)	1990-11-23	Aromatiske steroid-5-alfa-reduktaseinhibitorer
ATE275962T1 (de)	2004-10-15	Behandlung von prostatakrebs mit lhrh- antagonisten
BRPI0412439A (pt)	2006-09-05	compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições
ATE466832T1 (de)	2010-05-15	Neue curcuminanaloga und deren anwendungen
HUP0003194A2 (hu)	2001-07-30	Triozin-kináz-gátló alkalmazása prosztatarák kezelésére szolgáló szinergista gyógyszerkészítményben
BRPI0607523A2 (pt)	2009-09-08	compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos
MXPA05005314A (es)	2005-10-19	Compuestos de lapacona novedosos y metodos de uso de los mismos.
TR200700134T1 (tr)	2007-02-21	Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları.
MY137435A (en)	2009-01-30	Retinoid compounds (i)
NO20052028L (no)	2005-06-03	Pyridinderivater som CB2 reseptor modulatorer
NO20062679L (no)	2006-08-10	Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
EA200500170A1 (ru)	2005-10-27	Композиция на основе замещенных производных 1,3-дифенилпроп-2-ен-1-она, его получение и применения
IL152097A0 (en)	2003-05-29	Use of pyrazole derivatives for treating infertility
NO984075L (no)	1998-09-04	Kombinasjon av dehydroepiandrosteron og aromatasehemmere og anvendelse av denne kombinasjon for fremstilling av et legemiddel for behandling av en relativ og absolutt androgen mangel hos menn
SG149081A1 (en)	2009-01-29	Treatment of aromatase inhibitor therapy-related osteoporosis
PL370361A1 (en)	2005-05-16	Alkyl urea retinoid agonists i
NO20045343L (no)	2004-12-06	Ny kombinasjon for behandling av luftveisforstyrrelser
NO20070371L (no)	2007-03-08	N-substituerte piperidiner og anvendelse derav som farmasoytiske preparater
ATE327240T1 (de)	2006-06-15	2ß OXO-VORUSCHARIN UND DERIVATEN